Shark Tank's Namita Thapar Will Gain This Much From Emcure Pharma IPO
Thapar stands to achieve a 293-fold return on her initial investment at the upper end of the price band.
Shark Tank India judge, Namita Thapar, is set to reap substantial returns following her decision to partially divest her stake in Emcure Pharmaceuticals Ltd., where she is an executive director. Thapar stands to achieve a 293-fold return on her initial investment at the upper end of the price band set for the company’s initial public offering, according to the red herring prospectus.
The IPO, which opens on July 3, comprises a fresh issue worth Rs 800 crore and an offer for sale of 1.14 crore equity shares from shareholders and promoters. The price band has been fixed at Rs 960 to Rs 1,008 per share.
Thapar, holding 63,39,800 shares amounting to a 3.5% stake in Emcure, will sell 12,68,600 shares through offer for sale. Her average cost of acquisition per share stands at Rs 3.44, resulting in a total initial investment of Rs 2.18 crore.
Click here to check the live subscription status of Emcure Pharmaceuticals IPO.
Who Is Namita Thapar
Born on March 21, 1977, in Pune, Maharashtra, Thapar is an alumna of the Fuqua School of Business and a chartered accountant. She joined Emcure Pharmaceuticals as chief financial officer in 1999. Beyond her corporate roles, she has engaged in angel investing across various ventures as part of her stint in business reality show Shark Tank India. During the show’s first season, she invested Rs 10 crore in 25 companies. Thapar also founded Incredible Ventures Ltd., an education company promoting youth entrepreneurship. She also serves on the board of Fuqua School of Business and is a trustee of TiE Mumbai
Satish Ramanlal Mehta, managing director of Emcure Pharmaceuticals, is among other shareholders participating in the OFS. He owns a significant 41.85% stake in the company pre-issue. Mehta will offer up to 4.2 lakh equity shares, potentially realising a return of 52 times on his original investment at the upper price band.
Emcure Pharmaceuticals Financials
The IPO launch is expected to attract significant investor interest, given Emcure’s robust financial performance. In the financial year 2024, Emcure reported a revenue increase of over 11% to Rs 6,658 crore, while its net worth surged by 18% to Rs 2,952.3 crore.
The company has garnered attention in the pharmaceutical sector with operations spanning 70 countries and 13 manufacturing facilities in India.
